Current Shingles Vaccine Options and Effectiveness
Shingrix remains the primary shingles vaccine recommended by the CDC for adults 50 and older, with two doses administered 2 to 6 months apart. It is a recombinant zoster vaccine that provides strong protection against shingles and postherpetic neuralgia. Real-world effectiveness data shows Shingrix maintains over 85% efficacy against shingles for at least 4 years after vaccination. The vaccine is produced by GSK and is available at pharmacies, clinics, and doctor offices across the United States. For the latest CDC guidance, see the official CDC shingles vaccine page.
A newer shingles vaccine alternative, Zostavax, is a live attenuated vaccine that was discontinued in the United States as of November 2020, making Shingrix the only currently available shingles vaccine in the U.S. market. Zostavax had lower efficacy rates, around 51% for shingles prevention, and its discontinuation shifted the entire market to recombinant vaccine technology. Patients who previously received Zostavax are still advised to get Shingrix for stronger and longer-lasting protection. The shift reflects a broader industry trend toward more effective subunit and recombinant vaccines.
Cost, Insurance Coverage, and Financial Considerations
The average retail price for Shingrix is approximately $325 per dose, making the full two-dose series around $650 out-of-pocket without insurance. Most private health insurance plans, including Medicare Part D, cover Shingrix with little to no copay for eligible beneficiaries. The Affordable Care Act requires most marketplace plans to cover CDC-recommended vaccines without cost-sharing when administered in-network. Patients should verify coverage with their specific plan, as formularies and pharmacy networks can affect final costs. For details on Medicare vaccine coverage, see the official Medicare.gov vaccine information page.
Financial assistance programs and manufacturer coupons from GSK can reduce the cost for uninsured or underinsured patients. Some health systems and retail pharmacy chains offer bundled pricing or discount programs for the shingles vaccine series. The vaccine is classified as a preventive service under many health plans, which influences how it is billed and covered differently from therapeutic drugs. Investors tracking the vaccine market should note that GSK's vaccine division continues to be a significant revenue contributor, with Shingrix driving strong growth in the adult vaccines segment.
Market Landscape and Emerging Vaccine Developments
The global shingles vaccine market is dominated by Shingrix, which generated billions in annual revenue for GSK and reshaped the competitive landscape. Other pharmaceutical companies are researching next-generation shingles vaccines, including mRNA-based candidates that could offer improved stability and scalability. Moderna and Pfizer are among the firms exploring mRNA technology for shingles, building on their success with COVID-19 mRNA vaccines. These developments could introduce new shingles vaccine options within the next several years, pending clinical trial results and regulatory approvals.
Regulatory pathways for new shingles vaccines involve rigorous Phase 3 clinical trials and FDA review, with the Vaccines and Related Biological Products Advisory Committee providing expert recommendations. The CDC's Advisory Committee on Immunization Practices then issues final guidance on usage and scheduling once a vaccine is approved. Market analysts project continued strong demand for shingles vaccines as the population ages and awareness of shingles risk increases. For background on FDA vaccine approval processes, see the official FDA vaccines page.